epirubicin has been researched along with Duncan Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S | 1 |
| Browne, PV; Daly, PA; Duggan, C; Enright, H; Gardiner, N; Kennedy, MJ; McCann, SR; O'Connell, N | 1 |
1 trial(s) available for epirubicin and Duncan Disease
| Article | Year |
|---|---|
Effective progenitor cell mobilization in lymphoproliferative disorders using ifosfamide, epirubicin and etoposide (IEV).
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Lymphoma; Lymphoproliferative Disorders; Male; Middle Aged; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2001 |
1 other study(ies) available for epirubicin and Duncan Disease
| Article | Year |
|---|---|
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine | 2006 |